14/10/2026
đŦ A Promising Case in Precision Oncology!
Complete metabolic remission in MET exon 14-mutated NSCLC following dose-frequency-modified Tepotinib after Capmatinib intolerance. An interesting insight into personalized cancer treatment.
đ Read the case report: https://www.cureus.com/articles/502780-complete-metabolic-remission-with-dose-frequency-modified-tepotinib-following-capmatinib-intolerance-in-met-exon-14-mutated-non-small-cell-lung-cancer-nsclc-a-case-report
MET exon 14 (METex14) skipping mutations occur in a subset of non-small cell lung cancer (NSCLC) cases, mostly affecting older patients with multiple comorbidities. Selective MET tyrosine kinase inhibitors (TKIs) capmatinib and tepotinib represent the standard of care; however, real-world management...